DarDoc Research

GLP-1 Trial & Approval Tracker

All studies

SYNCHRONIZE-1 trial results

Adults with obesity or overweight with a related condition, without diabetes.

Survodutide
Phase
Phase 3
Follow-up
76 weeks
Randomised
726
Sponsor
Boehringer Ingelheim
Publication
New England Journal of Medicine · 2026

Double-blind, placebo-controlled. Treatment-regimen estimand. The trial randomised 726 participants and analysed 725.

Mean body weight change at 76 weeks
  • Survodutide up to 3.6 mg−12.2%
  • Survodutide up to 6.0 mg−13.0%
  • Placebo−5.4%
Mean body weight change at 76 weeks
Trial armResult
Survodutide up to 3.6 mg−12.2%
Survodutide up to 6.0 mg−13.0%
Placebo−5.4%
Participants with at least 5% weight loss at 76 weeks
Trial armResult
Survodutide up to 3.6 mg72.6%
Survodutide up to 6.0 mg71.9%
Placebo46.3%

Safety. Gastrointestinal adverse events were more common with survodutide than placebo.

Published paper PubMed abstract NCT06066515